The global Premenstrual Syndrome Treatment Market was valued at $1,129 million in 2018, and is projected to reach $1,516 million by 2026, registering a CAGR of 3.7% from 2019 to 2026.
Premenstrual syndrome or PMS refers to physical & emotional symptoms, which occur one to two weeks before the initiation of woman's menses. It is characterized by symptoms such as acne, tender breasts, mood swings, bloating, fatigue, and irritability.
The premenstrual syndrome treatment market is expected to experience a significant growth during the forecast period, owing to increase in awareness among patients, higher number of target population, rise in demand for PMS drugs, and easy availability of drugs.
For instance, according to the American Psychiatric Association, almost 90% of women of child bearing age experience premenstrual symptoms and less than 10% are diagnosed with premenstrual dysphoric disorder (PMDD). Thus, increase in prevalence of PMS is anticipated to fuel the demand for drugs, thereby driving the premenstrual syndrome treatment market growth. In addition, campaigns from government and non-government organizations to elevate female health status and education supports the market growth. However, unknown etiology and pathophysiology of PMS is anticipated to hamper the market growth.
Premenstrual Syndrome Treatment Market Segmentation
The global premenstrual syndrome treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, it is classified into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Based on type it is classified as prescription and OTC. According to distribution channel, the market is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Based on drug type, the premenstrual syndrome treatment market is categorized into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Presently, analgesics is the major revenue contributing segment, and is estimated to show a significant market growth during the forecast period due to higher adoption of analgesics as first line treatment for the management of PMS.
Analgesics drugs such as ibuprofen, acetaminophen, diclofenac, naproxen are widely used in management symptoms of PMS. These analgesics are generally used to reduce PMS symptoms such as stomach cramps, headache, muscle pain, joint pain and others. These drugs are available over the counter without a prescription but their overuse may cause adverse effects.
By Drug Type
Analgesics is projected as one of the most lucrative segment.
According to distribution channel, the premenstrual syndrome treatment is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict significant growth during the forecast period, due to rise in preference for online purchasing of drugs over traditional methods, increase in awareness of online providers, and rise in number of internet users.
By Distribution Channel
Drug Store and Retail Pharmacy holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
Asia-Pacific Premenstrual Syndrome Treatment Market
Asia-Pacific presents lucrative opportunities for the key players operating in the premenstrual syndrome treatment market, owing to the growth in awareness regarding premenstrual syndrome treatment, growth in healthcare awareness, and rise in adoption of premenstrual syndrome treatment products. Moreover, improvement in healthcare infrastructure, rise in number of target population, surge in healthcare reforms, and technological advancements in the field of healthcare further contribute to the market growth. Some other factors such as increase in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, due to high population base is expected to drive the growth of premenstrual syndrome treatment market in this region.
Asia-Pacific region would exhibit the highest CAGR of 5.1% during 2019-2026.
The key players profiled in this report include ABBVIE INC., AstraZeneca plc., BASF Corporation, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly And Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., and Shionogi Inc.
Key Benefits for Stakeholders:
- The study provides an in-depth analysis of the premenstrual syndrome treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers the Premenstrual syndrome treatment market analysis from 2018 to 2026, which is expected to enable stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis of all the four major geographical regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global Premenstrual syndrome treatment market growth.
Premenstrual Syndrome Treatment Market Report Highlights
By Drug Type
By Distribution Channel
Key Market Players
Shionogi Inc., Eli Lilly And Company., Pfizer Inc., ABBVIE INC., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd, Bayer AG., GlaxoSmithKline Plc., BASF Corporation, AstraZeneca plc
Different form of drug such as analgesics, antidepressants, oral contraceptives, and ovarian suppression agents are used in the management of PMS. The adoption of premenstrual syndrome therapeutics is expected to increase due to rise in the number of target population across the world and growth in awareness about premenstrual syndrome treatment in developing countries.
Ride in prevalence of PMS, increase in popularity of drug therapy, and surge in awareness regarding premenstrual syndrome treatment significantly boost the growth of the market. In addition, easy availability of drugs and unhealthy lifestyle can further support the market growth. However, unknown etiology of the disease is anticipated to hamper the market growth.
North America is expected to remain dominant during the forecast period, due to higher adoption of premenstrual syndrome treatment products, increased number of target population, presence of advanced healthcare facilities, easy availability of drugs, and early detection of this disease with higher health awareness among the general population drives the market growth. In addition, Asia-Pacific is expected to offer lucrative growth opportunities for the key market players during the forecast period, owing to rise in number of PMS affected population and awareness related to PMS.